SUBSCRIBE
SUBSCRIBE

Agenus Inc.

NEWS
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Incyte Corporation, Agenus Strike $410 Million+ Immuno-Oncology Antibodies Pact
January 9, 2015
 · 
2 min read
Load More
JOBS
IN THE PRESS
Press Releases
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
June 25, 2026
 · 
4 min read
Press Releases
Agenus Announces Virtual 2026 Annual Shareholders Meeting
June 3, 2026
 · 
1 min read
Press Releases
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
May 22, 2026
 · 
8 min read
Press Releases
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
May 22, 2026
 · 
9 min read
Press Releases
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
May 17, 2026
 · 
9 min read
Press Releases
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
May 11, 2026
 · 
15 min read
Press Releases
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
May 5, 2026
 · 
3 min read
Press Releases
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
April 22, 2026
 · 
5 min read
Press Releases
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
April 21, 2026
 · 
7 min read
Press Releases
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
April 3, 2026
 · 
4 min read
Load More